Table 2.
Individual patient details.
| # | Age | ER/PR/ HER2 |
Stage at Diagnosis | Transplant Regimen | RT Site | RT Dose (Gy) | RT Fx | Status | Subsequent Treatment * |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | −/−/− | II | MEL | T8 | 35 | 14 | Deceased (7.15 yrs) w/distant progression (5.8 yrs; widespread, no local) | Chemotherapy |
| 2 | 57 | −/−/+ | II | MEL | Pretracheal nodes | 37.5 | 15 | Deceased (0.7 yrs) w/distant progression (0.2 yrs; widespread, no local) | Chemotherapy, HER2-directed therapy |
| 3 | 44 | +/−/− | IV | MEL + STAMP | T4 | 40 | 20 | Alive (13.1 yrs) w/o progression | None |
| 4 | 57 | +/+/− | UK (III or less) | MEL | Sternum | 40 | 20 | Deceased (2.4 yrs) w/distant progression (0.4 yrs; widespread, no local) | Chemotherapy, antiestrogen therapy |
| 5 | 43 | +/+/+ | III | MEL + STAMP | Rib | 45 | 25 | Alive (6.8 yrs), w/distant progression (2.8 yrs; lung), NED | Wedge resection, chemotherapy, antiestrogen therapy, HER2-directed therapy |
| 6 | 32 | +/+/− | II | MEL + STAMP | Iliac crest | 43.2 | 24 | Alive (12.8 yrs) w/distant progression (6.5 yrs; widespread, no local) | Chemotherapy, palliative radiation, antiestrogen therapy |
| 7 | 40 | +/−/− | II | MEL + STAMP | Sternum, scapula, sacroiliac joint | 40 | 20 | Deceased (2.4 yrs) w/distant progression (1.1 yrs; widespread, no local) | Chemotherapy, antiestrogen therapy |
| 8 | 44 | +/+/− | IV | MEL + STAMP | Sternum | 50.4 | 28 | Alive (15.1 yrs) w/local and distant progression (1.1 yrs; widespread) | Chemotherapy, antiestrogen therapy |
| 9 | 55 | +/+/+ | IV | MEL + STAMP | Liver | 45 | 25 | Alive (7.2 yrs) w/o progression | None |
| 10 | 42 | +/+/− | II | MEL + STAMP | T12, L2 | 35 | 14 | Deceased (8.3 yrs) w/local and distant progression (3.9 yrs; widespread) | Chemotherapy, palliative radiation, antiestrogen therapy |
| 11 | 42 | +/+/+ | IV | MEL + STAMP | Contralateral supraclavicular node | 50.4 | 28 | Alive (13.5 yrs), w/distant progression (1.0 yrs; brain), NED | Stereotactic radiosurgery |
| 12 | 48 | +/+/− | IV | MEL + STAMP | Bilateral acetabulum | 39.9 | 15 | Alive (13.3 yrs) w/distant and local progression (3.9 yrs; widespread) | Chemotherapy, palliative radiation, antiestrogen therapy |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MEL, melphalan; carboplatin, thiotepa, and cyclophosphamide, STAMP; RT, radiation therapy; Gy, Gray; Fx, fractions; NED, no evidence of disease. * In addition to standard adjuvant antiestrogen or HER2-directed therapy.